Twist Bioscience Corporation

NASDAQ:TWST

Medical - Diagnostics & Research

Healthcare
$116.35 +2.59%

+$2.15 today

Market cap
$7.66B
Beta
2.21
P/E (TTM)
-64.5
EPS (TTM)
-$1.32
52W Low $23.30High $88.46

Volume 2.23M

Average 1.53M

TWST Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Twist Bioscience CorporationNASDAQ: TWST

Cash & Equivalents · Q4 FY2026 · quarter ended Sep 2026

Cash & equivalents rises 191.7% from a year ago

Cash & equivalents stood at $533.99M at the end of Q4 FY2026, up 191.7% from a year earlier and up 354.7% from the prior quarter. Over 3 fiscal years it compounded at +23.1% a year.

Context

  • Cash & equivalents amounted to 47.6% of total assets at the end of Q4 FY2026, up 19.1 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2026 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +191.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$533.99M+354.7% QoQ
Last fiscal yearSep 2026
$533.99M+191.7% YoY
Year agoSep 2025
$183.05M+191.7% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+191.7%——
1 year+191.7%——
3-year CAGR+23.1%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2026
533.99M USD
Year-over-year change
+191.7%
4-year CAGR
+9.0%

Cash & Equivalents vs competitors

How TWST compares with its peers on the latest reported figures

  • TWST's Sep 2026 cash & equivalents of $533.99M is the lowest of the 2 companies compared; the peer median is $606.78M.
  • Its year-over-year change of +191.7% is the highest of 2, against a peer median of -14.4%.
  • Cash & equivalents amounts to 47.6% of total assets for TWST, versus a peer median of 20.6%.
TWST Competitors Peer median
Cash & Equivalents for TWST and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RGENRepligen CorporationJun 2026$606.78M -14.4%+2.6%20.6%
TWSTTwist Bioscience CorporationSep 2026$533.99M +191.7%+23.1%47.6%
Peer median (excluding TWST) $606.78M-14.4%+2.6%20.6%

Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Cash & Equivalents378.69M286.47M226.32M183.05M533.99M
Short-term Investments126.28M49.94M50.08M49.39M47.92M
Net Receivables40.29M44.06M34.9M57.32M70.19M
Inventory39.31M32.06M24.08M28.31M46.41M
Other Current Assets011.72M11.4M14.9M38.71M
Total Current Assets596.48M424.26M346.78M332.97M737.22M
Property, Plant & Equipment (Net)214.39M203.36M161.35M151.66M191.6M
Goodwill85.81M85.81M85.81M82.2M82.2M
Intangible Assets59.74M54.48M14.48M13.43M34.16M
Long-term Investments02.81M1.53M54.34M68.09M
Tax Assets00000
Other Non-current Assets4.96M5.68M4.38M7.28M8.54M
Total Non-current Assets364.9M352.15M267.55M308.9M384.58M
Total Assets961.38M776.4M614.32M641.86M1.12B
Account Payables20.09M14.05M1.63M11.09M24.85M
Short-term Debt00013.82M0
Tax Payables3.66M4.37M2.73M00
Deferred Revenue3.48M3M2.13M6.88M0
Other Current Liabilities39.62M26.25M34.61M23.78M54.19M
Total Current Liabilities90.66M73.32M71.01M91.41M125.81M
Long-term Debt00061.75M0
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities60K475K407K(46M)21.45M
Total Non-current Liabilities81.33M79.65M70.63M77.5M107.98M
Total Liabilities171.99M152.97M141.63M168.9M233.79M
Common Stock00001K
Retained Earnings(828.42M)(1.03B)(1.24B)(1.32B)(1.45B)
Accumulated OCI(1.84M)(756K)(522K)(627K)(680K)
Other Stockholders Equity00002.34B
Minority Interest00000
Total Equity789.39M623.43M472.69M472.96M888.02M
Total Debt94.91M94.07M85.03M137.32M94.99M
Net Debt(283.78M)(192.4M)(141.29M)(45.73M)(439.01M)

Twist Bioscience Corporation

NASDAQ:TWST

Intrinsic Alpha fair value

Locked

Current Price

$116.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.